Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies.

By D. Auld, T. Kornecook, S. Bastianetto, R. Quirion. Progress in neurobiology, 2002

672 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The Cholinergic Hypothesis of Age and Alzheimer's Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development (2003, background): “Examples from the post mortem AD literature include alterations in high-affinity choline uptake , impaired acetylcholine release, deficits in the expression of nicotinic and muscarinic receptors, and dysfunctional neurotrophin support (reviewed in Auld et al., 2002).”
Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development (2007, background): “Alzheimer's disease and cognitive impairments A convincing body of data indicate that mAChRs have central roles in facilitating cognitive function”
Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies (2024, positive): “97,99 It has been observed that cholinergic neurons in the NBM region are particularly susceptible to degeneration and loss in AD.”
Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models (2014, neutral): “These disturbances include hyperactivity, stereotypic behaviors, and home cage activity disturbances (Dodart et al., 1999; Janus and Westaway, 2001; Auld et al., 2002; Dumont et al., 2004; Hyde et al., 2005; Cheng et al., 2007; Gil-Bea et al., 2007; Gimenez-Llort et al., 2007; Pietropaolo et al.,…”